Assertio Holdings Faces Allegations of Clinical Data Fraud Amid Increased Investor Scrutiny
- Buxton Helmsley Group shifts to short interest in Assertio Holdings amid allegations of clinical data fraud.
- Assertio's CEO claims internal investigation dismissed allegations, but BHG criticizes the company's reluctance to engage with whistleblowers.
- BHG calls for a Senate investigation due to concerns over clinical data integrity and Assertio's financial disclosures.
Heightened Scrutiny on Assertio Holdings Amid Allegations of Clinical Data Fraud
In a significant move, the Buxton Helmsley Group, Inc. (BHG), a New York City-based investment fund manager, transitions from a long equity position to a short interest in Assertio Holdings, Inc. (NASDAQ: ASRT). This strategic pivot is driven by BHG's allegations of product-related fraud linked to Spectrum Pharmaceuticals, now fully owned by Assertio. Following the resignation of Assertio's Chairman and a board member, effective November 7, 2024, BHG intensifies its call for an investigation by the Senate Committee on Health, Education, Labor & Pensions. The request comes in the wake of a 20-page exposé released by BHG, which includes testimony from whistleblowers presenting substantial evidence of clinical data fraud tied to Assertio’s products.
BHG's concerns center around the integrity of clinical data used to support Assertio's offerings, particularly focusing on Rolvedon, a drug that has faced scrutiny in the past. During Assertio’s earnings call on November 11, 2024, CEO Brendan O’Grady asserts that the company's internal investigation into the allegations was comprehensive enough to dismiss any further inquiries. However, BHG criticizes this stance, arguing it reflects a troubling reluctance to engage with whistleblowers or to acknowledge the evidence they provide. This refusal to confront serious allegations raises alarm bells regarding patient safety and public health implications, prompting BHG to seek a formal hearing where these whistleblowers can present their findings to federal agencies, including the U.S. Department of Health and Human Services (HHS), the Food and Drug Administration (FDA), and the Securities and Exchange Commission (SEC).
Adding to the controversy, BHG expresses dismay at Assertio's auditor, Grant Thornton, for continuing to endorse the company's financial statements despite apparent breaches of the Committee of Sponsoring Organizations of the Treadway Commission (COSO) Framework. BHG argues that this endorsement undermines the credibility of Assertio’s financial disclosures and raises further questions about the company's governance practices. The situation illustrates a pivotal moment for Assertio Holdings, as it navigates the ramifications of these allegations while striving to maintain its reputation in the competitive pharmaceutical landscape.
In light of these developments, BHG's call for a thorough investigation underscores the pressing need to uphold clinical data integrity within the pharmaceutical industry. The consequences of overlooking such serious allegations could extend beyond corporate governance and impact broader public trust in healthcare products. As the situation unfolds, all eyes remain on Assertio Holdings and its response to the mounting scrutiny.